About VAHO
Founded in 1990, the Virginia Association of Hematologists and Oncologists (VAHO) is the largest oncology professional organization in the state. VAHO comprises a powerful community of oncologists, nurse practitioners, physician assistants, pharmacists, and other multidisciplinary care providers involved in the treatment of patients with cancer.
Events Calendar view all
2026 Spring MeetingThu |
Industry News view all
11/21/2025[Duplicate] FDA Approves BeiGene’s TEVIMBRA® (tislelizumab-jsgr) First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with ChemotherapyNew indication based on results from a global Phase 3 trial demonstrating TEVIMBRA plus chemotherapy significantly improved overall survival for patients with advanced gastric cancers Second FDA approval for TEVIMBRA in 2024 |
11/21/2025FDA approves (Zepzelca) lurbinectedin in combination with atezolizumab or atezolizumab and hyaluronidase-tqjs for extensive-stage small cell lung cancerOn October 2, 2025, the Food and Drug Administration approved lurbinectedin (Zepzelca, Jazz Pharmaceuticals, Inc.) in combination with atezolizumab (Tecentriq, Genentech Inc.) or atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech Inc.) for the maintenance treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first-line induction therapy with atezolizumab or atezolizumab and hyaluronidase-tqjs, carboplatin, and etoposide. Full prescribing information for Zepzelca, Tecentriq, and Tecentriq Hybreza will be posted on Drugs@FDA. |
11/21/2025FDA approves (LIBTAYO) cemiplimab-rwlc for adjuvant treatment of cutaneous squamous cell carcinomaOn October 8, 2025, the Food and Drug Administration approved cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals Inc.) for the adjuvant treatment of adults with cutaneous squamous cell carcinoma (CSCC) at high risk of recurrence after surgery and radiation. Second FDA approval for TEVIMBRA in 2024 |
